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Introduction
Chronic kidney disease (CKD) is a growing health bur-
den worldwide, as well as in Korea [1]. The numbers of 
patients with CKD and end-stage renal disease (ESRD) 
are increasing rapidly [2,3]. Not only CKD is a significant 
factor in morbidity and mortality, but the medical ex-
penses for management of CKD are increasing remark-
ably.
In order to broaden knowledge regarding the risk fac-
tors for CKD progression and adverse outcomes, the 
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Chronic Kidney Disease (KNOW-CKD) was established 
with the support of the Korea Center for Disease Control 
and Prevention (KCDC) [4]. The study protocol was ap-
proved by the ethical committee at each participating 
center (Supplementary materials, available online). From 
2011 until 2016, the KNOW-CKD recruited 2,238 adult 
patients with CKD from stage G1 to G5 who were not re-
ceiving renal replacement therapy from nine tertiary care 
hospitals throughout Korea [5]. All the subjects being 
ethnic Koreans, the KNOW-CKD is expected to provide 
high-level evidence from Koreans on the clinical courses 
and clinical and biological factors for CKD progression 
and/or adverse outcomes, and diverse deficits related 
to CKD such as cardiovascular comorbidity, anemia, 
mineral metabolic derangements, quality of life (QOL), 
and health habits. Unlike other CKD cohort studies such 
as the Chronic Renal Insufficiency Cohort (CRIC) of the 
United States [6,7] or the Chronic Kidney Disease Japan 
Cohort (CKD-JAC) of Japan [8], the KNOW-CKD study 
includes CKD at early stages (stages G1 and G2) as well as 
advanced stages, providing a platform on which to inves-
tigate the courses of early CKD over the long term.
As of December 2019, the KNOW-CKD has published 
over 50 articles in international peer-reviewed journals. 
The present article provides the basic design and sum-
mary of the major findings from the KNOW-CKD study.
Study design, recruitment, and follow-up status
Details of the rationale and design of the KNOW-CKD 
study have been described previously [4]. Briefly, for 
Phase I of the KNOW-CKD study, 2,238 subjects with 
CKD were recruited from nine university-affiliated tertia-
ry-care hospitals throughout Korea from 2011 until 2016. 
Nephrologists, epidemiologists, specialists in laboratory 
medicine, and biostatisticians have participated in this 
study. The study is funded and supervised by the KCDC. 
The protocol summary is also registered at the Clinical-
Trials.gov with accession number NCT01630486. The 
participants were all ethnic Koreans, aged between 20 
and 75 years, with CKD stages from G1 to G5 (pre-dialy-
sis). CKD stages were defined on the basis of the estimat-
ed glomerular filtration rate (eGFR) calculated using the 
CKD Epidemiology Collaboration (CKD-EPI) (cr) formula 
[9]. The serum creatinine was measured at a central labo-
ratory (LabGenomics, Seongnam, Korea), using an assay 
traceable to the international reference material. 
All enrolled subjects were categorized into the fol-
lowing subgroups: glomerular diseases (GN), diabetic 
nephropathy (DN), hypertensive nephropathy (HTN), 
polycystic kidney disease (PKD), and unclassified, based 
on the etiology of CKD. HTN and PKD were oversampled 
in order to compare the four major causative diseases of 
CKD. The clinical information and laboratory tests per-
formed at each study visit are depicted in Table 1 [5].
Composite renal events were defined as doubling of se-
rum creatinine, eGFR halving, or development of ESRD. 
ESRD was defined as starting maintenance dialysis for 
more than three months or receiving kidney transplan-
tation. CV events were defined as any first event of the 
following: acute myocardial infarction, unstable angina, 
ischemic or hemorrhagic cerebral stroke, congestive 
heart failure, symptomatic arrhythmia, aggravated valvu-
lar heart disease, pericardial disease, abdominal aortic 
aneurysm, and severe peripheral arterial disease that 
required hospitalization, interventions, or therapy during 
follow-up. Data on the time and specific causes of mor-
tality were obtained either from hospital records or from 
the Korean Statistical Information Service (KOSIS). Other 
events such as all-cause hospitalization, surgery, and 
fracture were also collected during the follow-up period. 
All the events described above were recorded on a special 
report form and further adjudicated by the Central Adju-
dication Committee of the KNOW-CKD study.
The baseline characteristics of the study subjects are 
described in Table 2.
As of March 31, 2019, among 2,238 subjects enrolled 
in the study, there were 107 deaths and 165 fatal or non-
fatal CV events after 5.0-year (median) follow-up. Five 
hundred thirty three subjects developed ESRD (Table 3, 
Fig. 1).
We subsequently summarize the major findings of the 
KNOW-CKD study in several areas: 1) socio-economics 
and health-related habits, 2) CV comorbidity, 3) ane-
mia, 4) mineral bone disease, 5) nutrition and QOL, 6) 
biomarker discovery studies, 7) clinical courses and out-
comes, and 8) international comparison.
Socio-economics and health-related habits
Socio-economic status (SES), defined by educational at-
tainment and income levels, contributes to a complex set 
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of socio-economic determinants, including medical in-
surance, transportation, stress level, housing quality, and 
accessibility to medical care [10]. Such determinants may 
interact and combine to affect health outcomes. Among 
the KNOW-CKD participants, lower SES was significantly 
associated with left ventricular hypertrophy, which is a 
major predictor of future CV outcomes [11]. Currently, 
analysis of longitudinal follow-up data is underway and 
is expected to reveal whether lower SES is associated with 
the risk for CKD progression or poorer CV outcomes.
While increased body mass index (BMI) is a well-
established CVD risk factor in the general population, it 
is paradoxically associated with survival benefits in CKD 
and ESRD patients [12,13]. In contrast to BMI, anthro-
pometric indices representing central obesity such as 
waist-to-hip ratio (WHR) and waist circumference (WC) 
are suggested to be directly associated with CVD and 
mortality. The KNOW-CKD subjects were categorized 
into 6 groups according to a combination of BMI (normal, 
overweight, obese) and WHR (lower or higher than sex-
specific median WHR). Here, the normal BMI and higher 
WHR group had the highest risk of coronary artery calci-
fication (CAC) compared with the normal BMI and lower 
WHR group (odds ratio, 2.104; 95% confidence interval 
[CI], 1.074-4.121). Thus, BMI and WHR-two predictors 
of obesity-can help to discriminate CVD risk in Korean 
CKD patients [14].
The KNOW-CKD investigated the effects of health 
habits on CKD outcome. The study collected detailed 
information on exercise, alcohol drinking, and smoking 
through self-reported questionnaires. Compared with 
non-drinkers, regular and occasional binge drinkers had 
Table 1. Sequence and schedule of KNOW-CKD study clinic visits and procedures
Parameter Screen At entry 6 mo 1 yr 2 yr 3 yr 4 yr 5 yr 6 yr 7 yr 8 yr 9 yr 10 yr
Informed consent ●
Demographic information, Medical 
History
●
Recent events ● ● ● ● ● ● ● ● ● ● ●
Medications ● ● ● ● ● ● ● ● ● ● ● ●
HRQOL/Health related questionnaire ● ●
BP/anthropometry ● ● ● ● ● ● ● ● ● ● ● ●
CBC, chemistry, Cra, eGFR, Cystatin Ca, 
HbA1c
● ● ● ● ● ● ● ● ● ● ● ●
Lipid panel, CRP, iron panel ● ● ●
Intact PTHa, 25 Da, 1,25 Da, troponin Ta ● ● ●
UA with microscopy ● ● ●
24HU – Na/K/Ca/P/Cr/Urea/Uric 
acid/protein, Spot urine electrolytesa, 
albumina, proteina, osmolalitya, Cra
● ● ●
ECG, chest X ray ● ● ● ●
EchoCG, PWV, ABI, Coronary CT, LS 
spine lateral X-ray, DEXA BMD
● ●
Biosamples for DNA ●
Serum/urine biosample ● ● ● ● ● ● ● ●
Fundus exam (DM subgroup) ●
Abdomen CT (PKD subgroup) ● ● ● ● ● ●
Family screen (PKD subgroup) ●
1,25 D, 1,25-dihydroxyvitamin D; 24HU, 24-hour urine; 25 D, 25-hydroxyvitamine D; ABI, ankle-brachial index; BP, blood pressure; CBC, complete blood count; Cr, 
creatinine; CRP, C-reactive protein; CT, computed tomography; DEXA BMD, dual energy x-ray absorptiometry bone mineral density; DM, diabetes mellitus; ECG, 
electrocardiogram; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; HRQOL, health-related quality of life; KNOW-CKD, KoreaN Cohort Study 
for Outcomes in Patients With Chronic Kidney Disease; LS, lumbosacral; PKD, polycystic kidney disease; PTH, parathyroid hormone; PWV, pulse wave velocity; UA, 
urinalysis.
aMeasured at the central laboratory.
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Table 2. Baseline demographic and clinical characteristics of KNOW-CKD subjects at study entry
Cause of CKD Total (n = 2,238) GN (n = 810) DN (n = 519) HTN (n = 409) PKD (n = 364) P
Age (yr) 53.7 ± 12.2 49.8 ± 12.1 59.3 ± 9.4 59.6 ± 10.8 47 ± 10.6 < 0.001*
Sex
   Male 1,369 (61.2) 451 (55.7) 357 (68.8) 295 (72.1) 184 (50.5) < 0.001†
   Female 869 (38.8) 359 (44.3) 162 (31.2) 114 (27.9) 180 (49.5)
Educational attainment
   Illiteracy 15 (0.8) 6 (0.9) 1 (0.2) 5 (1.4) 2 (0.6) < 0.001†
   Graduated elementary school 239 (10.8) 56 (8.0) 71 (16.0) 53 (14.7) 19 (5.6)
   Graduated middle school 259 (11.7) 62 (8.9) 76 (17.2) 41 (11.4) 24 (7.0)
   Graduated high school 785 (35.3) 268 (38.3) 145 (32.7) 110 (30.6) 98 (28.7)
   Graduated college or more 906 (40.8) 308 (43.9) 150 (33.8) 151 (42.0) 198 (58.1)
Smoking
   Never smoker 1,202 (53.9) 478 (59.1) 240 (46.8) 183 (44.9) 228 (62.6) < 0.001†
   Current smoker 349 (15.7) 115 (14.2) 84 (16.4) 71 (17.4) 55 (15.1)
   Former smoker 677 (30.4) 216 (26.7) 189 (36.8) 154 (37.7) 81 (22.3)
Comorbid disease
   Coronary artery disease 118 (5.3) 14 (1.7) 60 (11.6) 32 (7.8) 2 (0.5) < 0.001†
   Peripheral vascular disease 78 (3.5) 13 (1.6) 32 (6.2) 20 (4.9) 1 (0.3) < 0.001†
   Cerebrovascular disease 135 (6.0) 19 (2.3) 51 (9.8) 38 (9.3) 21 (5.8) < 0.001†
   Diabetes 755 (33.7) 70 (8.6) 519 (100.0) 72 (17.6) 12 (3.3) < 0.001†
   Hypertension 2,150 (96.1) 785 (96.9) 513 (98.8) 407 (99.5) 314 (86.3) < 0.001†
   Congestive heart failure 34 (1.5) 7 (0.9) 12 (2.3) 10 (2.4) 2 (0.5) 0.025‡
   Arrhythmia 56 (2.5) 18 (2.2) 16 (3.1) 18 (4.4) 2 (0.5) 0.006†
Age-adjusted modified CCI
   Low (≤ 3) 1,174 (52.5) 627 (77.4) 24 (4.6) 153 (37.4) 317 (87.1) < 0.001†
   Moderate (4-5) 652 (29.1) 155 (19.1) 204 (39.3) 193 (47.2) 45 (12.4)
   High (6-7) 347 (15.5) 25 (3.1) 242 (46.6) 56 (13.7) 2 (0.5)
   Very high (8-9) 65 (2.9) 3 (0.4) 49 (9.4) 7 (1.7) 0 (0.0)
BMI (kg/m2) 24.6 ± 3.4 24.2 ± 3.3 25.2 ± 3.2 25.1 ± 3.5 23.5 ± 3 < 0.001*
BP variables
   Systolic BP (mmHg) 127.8 ± 16.2 123.4 ± 14.2 134.3 ± 18.5 127.8 ± 15.9 128.3 ± 13.3 < 0.001*
   Diastolic BP (mmHg) 77 ± 11.1 75.6 ± 10.1 75.7 ± 11.7 77.7 ± 11.5 81 ± 10.4 < 0.001*
   Pulse pressure (mmHg) 50.8 ± 12.2 47.8 ± 10.6 58.5 ± 13.4 50.1 ± 11.3 47.3 ± 9.8 < 0.001*
eGFR (mL/min/1.73 m2) 53.1 ± 30.7 60.1 ± 31.4 36.6 ± 21.9 42.3 ± 21.7 72.9 ± 32.9 < 0.001*
Urine protein/24 hr (mg/day) 1,353 ± 2,139 1,292 ± 1,524 2,664 ± 3,168 766 ± 1,133 178 ± 256 < 0.001*
ACEI or ARB therapy 1,907 (85.4) 726 (89.7) 448 (86.8) 333 (81.6) 285 (78.3) < 0.001†
CKD stage
   Stage G1 265 (11.8) 131 (16.2) 13 (2.5) 11 (2.7) 94 (25.8) < 0.001†
   Stage G2 419 (18.7) 180 (22.2) 44 (8.5) 48 (11.7) 118 (32.4)
   Stage G3a 403 (18.0) 163 (20.1) 72 (13.9) 95 (23.2) 52 (14.3)
   Stage G3b 484 (21.6) 158 (19.5) 131 (25.2) 112 (27.4) 45 (12.4)
   Stage G4 522 (23.3) 138 (17.0) 198 (38.2) 118 (28.9) 42 (11.5)
   Stage G5 (predialysis) 145 (6.5) 40 (4.9) 61 (11.8) 25 (6.1) 13 (3.6)
Data are presented as mean ± standard deviation or number (%).
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood pressure; CCI, Charlson comorbidity index; CKD, 
chronic kidney disease; DN, diabetic nephropathy; eGFR, estimated glomerular filtration rate; G, grade; GN, glomerulonephritis; HTN, hypertensive nephropathy; 
KNOW-CKD, KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease; PKD, polycystic kidney disease.
*P value evaluated by Kruskal-Wallis test; †P value evaluated by chi-square test; ‡P value evaluated by Fisher’s exact test.
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a 2.2-fold (95% CI, 1.38-3.46) and a 2.0-fold (95% CI, 
1.33-2.98) higher risk of CKD progression, respectively. 
This association was particularly evident in patients who 
had decreased kidney function and proteinuria [15].
Cardiovascular disease profile at study entry
Since CKD is associated with heavy CVD burden, thor-
ough CV evaluations including echocardiography, coro-
nary computed tomography, and pulse wave velocity 
(PWV) measurements were conducted at study entry and 
regularly thereafter. The overall prevalence of comorbid 
CVD at study entry was 14.4% in all study participants 
and was the highest in the DN subgroup followed by the 
HTN subgroup. The DN subgroup had more adverse 
CV risk profiles (higher systolic blood pressure (BP) and 
higher levels of cardiac troponin T, left ventricular mass 
index, coronary calcium score, and brachial-ankle PWV) 
than the other subgroups. These CV risk profiles were all 
inversely correlated with eGFR [16]. Metabolic acidosis 
defined as a serum bicarbonate level of < 22 mmol/L was 
independently associated with arterial stiffness [17]. Vig-
orous investigation to search for the risk factors and bio-
markers related to CVD is under way.
Coronary artery calcification
CAC is a well‐known predictor of CV events and high 
mortality in the general population [18] and in patients 
with CKD [19,20]. The KNOW-CKD investigated the clini-
cal and biochemical factors related to CAC. There was a 
gradual and independent association between low eGFR 
and CAC at the study entry in the KNOW-CKD subjects 
[21]. In view of arterial stiffness measured by PWV, the 
Table 3. Incidences of main outcomes from KNOW-CKD participants as of March 2019
Outcome  
events
Event rate per 1,000 person years
PTotal Cohort Diabetes Non-diabetes
Event number Incidence Event number Incidence Event number Incidence
ESRD 533 57.0 262 98.7 271 40.5 < 0.001
ESRD or eGFR halving 662 73.8 314 125.1 348 53.9 < 0.001
Any CV disease 165 16.2 88 28.1 77 10.9 < 0.001
   Coronary event 76 7.4 48 15.3 28 4.0 < 0.001
   CHF 9 0.9 5 1.6 4 0.6 0.121
   Ischemic stroke 26 2.5 17 5.4 9 1.3 < 0.001
   Cerebral hemorrhage 11 1.1 5 1.6 6 0.8 0.295
Death 107 10.1 62 18.6 45 6.2 < 0.001
CHF, congestive heart failure; CV, cardiovascular; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; KNOW-CKD, KoreaN Cohort Study for 
Outcomes in Patients With Chronic Kidney Disease.








































CRIC (eGFR 20 70 mL/min/1.73 m ) 2
eGFR halving
Figure 1. Incidences of major out-
comes of KoreaN Cohort Study for Out-
comes in Patients With Chronic Kidney 
Disease (KNOW-CKD) and comparison 
with the Chronic Renal Insufficiency 
Cohort (CRIC) cohort. CRIC comprises 
CKD subjects with estimated glomerular 
filtration rate (eGFR) between 20 to 70 
mL/min/1.73 m2. Therefore, it is more 
relevant to compare CRIC and KNOW-CKD 
at stages G3a-5, rather than total KNOW-
CKD subjects.
ESRD, end-stage renal disease.
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subjects with higher baPWV (brachial-ankle PWV) exhib-
ited higher prevalence of CAC, suggesting that increased 
arterial stiffness is independently associated with CAC 
[22].
Anemia
Anemia is a well-known complication in CKD and is as-
sociated with the progression of CKD, poor QOL, and in-
crease in morbidity and mortality. Overall prevalence of 
anemia in the KNOW-CKD cohort was 45.0%, and DN as 
a cause, advanced CKD stages, BMI, smoking, leukocyte 
count, serum albumin, iron markers, calcium, and phos-
phorus concentration were identified as independent 
risk factors for anemia [23].
Recently, hepcidin was found to be a key molecule 
mediating iron metabolism and transport. Binding of 
hepcidin to ferroportin, an iron-exporting transcellular 
channel, induces the internalization and degradation of 
ferroportin and disturbs iron efflux from cells to plasma, 
ultimately lowering serum iron levels and sequestering 
iron in iron-storage sites [24]. The KNOW-CKD showed 
from a large number of CKD patients that lower eGFR is 
associated with higher serum hepcidin levels, particular-
ly in advanced CKD. Iron supplementation was positively 
correlated with serum hepcidin levels, especially in pa-
tients with early CKD. The higher hepcidin level in eryth-
ropoiesis-stimulating agents (ESA) users, as compared 
with non-users, suggests that hepcidin is a key peptide 
involved in ESA resistance, suggesting a possible role of 
hepcidin modulation in anemia treatment [25]. Indices of 
iron profiles were analyzed in relation to anemia in CKD. 
Transferrin saturation and hepcidin were significantly 
associated with anemia status, whereas serum ferritin 
was not. Hepcidin was particularly associated with severe 
anemia in advanced CKD stages [26], suggesting a pos-
sible role of hepcidin as a predictive marker of anemia in 
CKD.
Mineral bone disease of CKD
In KNOW-CKD study patients, serum vitamin D levels 
began to decline in the early stages of CKD before signifi-
cant elevations in fibroblast growth factor 23 (FGF23) and 
intact parathyroid hormone (iPTH). Moreover, FGF23 el-
evation was observed concurrently with increased iPTH 
with declining eGFR [27], in contrast to Western popula-
tions. There is a stepwise decrease in serum Klotho con-
centration with the decline of eGFR [28]. The prevalence 
of osteoporosis was higher in advanced CKD patients [27]. 
Also, increased vascular calcification scores are noted in 
both early and advanced stages of CKD, similar to that of 
Western populations [27].
In female patients with CKD, increased serum osteo-
protegerin (OPG) levels were independently associated 
with decreased bone mineral density in the lumbar spine 
and total hip and with increased risk of osteoporosis. 
Therefore, measurement of serum OPG concentration 
may be useful as a predictor for determining bone loss in 
CKD patients [29].
Moreover, there may be a crosslink between the mark-
ers of bone mineral metabolism and those of anemia. 
The KNOW-CKD showed that elevated serum phospho-
rus and iPTH are associated with an increase in hepcidin, 
while elevated vitamin D levels are associated with a 
decrease in serum hepcidin levels after adjustment [30]. 
High FGF23 was associated with anemia at baseline and 
development of anemia during follow-up [31], which is 
consistent with the observation from the CRIC cohort 
[32]. Taken together, these findings suggest that correct-
ing mineral metabolic derangement may be a possible 
therapeutic approach in treating anemia in CKD.
Nutrition and QOL in CKD
Malnutrition or protein-energy wasting (PEW) in CKD 
is prevalent with decreasing renal function and is a strong 
indicator of adverse outcomes. Multiple mechanisms are 
involved in nutritional problems in CKD patients. Insuf-
ficient food intake caused by uremia-induced anorexia 
alone does not account for the unfavorable nutritional 
changes. There are additional contributing factors, such 
as chronic inflammation, acidosis, multiple hormonal 
disturbances, comorbidities, and physical inactivity [33]. 
The prevalence of PEW in the KNOW-CKD study was 
about 9.0% [34] according to the International Society of 
Renal Nutrition and Metabolism (ISRNM) criteria [35] 
and tended to increase with advanced stage in pre-dial-
ysis CKD. In the multivariate logistic regression model, 
PEW was independently associated with eGFR, total CO2, 
physical activity, diabetes, and high sensitivity C-reactive 
protein (hs-CRP) [34].
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Health-related quality of life (HRQOL) is a concept in 
QOL that focuses on the effects of illness, and specifically 
on the impact that treatment may have on QOL. It is gen-
erally accepted that HRQOL represents the positive and 
negative aspects of patients' symptoms, including emo-
tional, social, and cognitive functions, disease burden, 
and treatment side effects. Recently, HRQOL has been 
accepted as an important health outcome. Patients with 
advanced CKD have multiple, complex comorbid condi-
tions that can produce poor HRQOL [36]. The KNOW-
CKD study acquires information on HRQOL, SES such 
as occupation, academic year, monthly income, sleep 
quality and quantity, and health-related habits through 
patient-reported questionnaires at the study entry and 
regularly thereafter. There was a significant association 
between serum vitamin D levels and kidney disease 
component summary (KDCS) and mental component 
summary (MCS) scores in pre-dialysis CKD patients [37]. 
Sleep duration was also correlated with HRQOL in pa-
tients with CKD. Too long or short sleep durations were 
associated with poor HRQOL [38]. WC is a better indica-
tor of poor physical HRQOL than BMI. The association 
between WC and physical HRQOL is modified by age, 
sex, eGFR, and comorbidities such as diabetes and CVD 
[39].
The second phase of the KNOW-CKD study (KNOW-
CKD Phase II), which is scheduled to recruit 1,500 sub-
jects between 2019 and 2021, will emphasize nutritional 
assessment and evaluation of QOL and cognitive func-
tion change. It is strongly anticipated that the KNOW-
CKD Phase II will provide us with robust medical and 
clinical knowledge on the nutritional issues and QOL in 
CKD patients.
CKD progression
The KNOW-CKD defined the renal end-point as either 
eGFR halving or ESRD occurrence. The composite renal 
event was defined as one of the two renal events above. 
General risk factors of renal composite end-point from 
the KNOW-CKD are depicted in Table 4. As a surrogate of 
renal progression, eGFR slope was calculated based on 
the mixed model.
Elucidating and modulating the major risk factors of 
CKD to delay progression are the key aims of the KNOW-
CKD study. Regarding the association between obesity 
and CKD progression, there have been conflicting results. 
Here, we defined metabolic abnormality as the presence 
of three or more of the following five components: hy-
pertension, fasting glucose level ≥ 126 mg/dL or the pres-
ence of type 2 diabetes, triglyceride level > 150 mg/dL 
or use of lipid-lowering drugs, high-density lipoprotein 
cholesterol level ≤ 40 mg/dL in men and ≤ 50 mg/dL in 
women, and hs-CRP level > 1 mg/L. Obesity was defined 
as BMI ≥ 25 kg/m2. The KNOW-CKD showed that both 
metabolic abnormalities and obesity are associated with 
a significantly increased risk for CKD progression. Nota-
bly, obese patients without metabolic abnormalities also 
have an elevated risk for CKD progression (Fig. 2) [40]. 
Another study investigated the effect of dietary salt intake 
on CKD progression using 24-hour urinary Na excretion 
as a proxy [41]. Here, it was shown that, compared with the 
reference group (urinary Na excretion 104.2-145.1 mEq/
day), the highest quartile group was associated with 1.8 
times higher risk of composite renal outcome (urinary Na 
excretion ≥ 192.9 mEq/day, P = 0.015) in a multivariable 
hazards model (Fig. 3) [41]. Arterial stiffness measured by 
Table 4. Risk factors for renal composite end-points






   20-39 81 (25.6) 1
   40-49 131 (29.7) 0.73 0.55-0.96
   50-59 207 (31.7) 0.52 0.40-0.68
   60-69 182 (32.3) 0.41 0.31-0.54
   ≥ 70 61 (29.6) 0.34 0.24-0.48
Gender
   Female 266 (31.6) 1
   Male 396 (29.6) 1.14 0.97-1.33
DM
   Non-DM 348 (24.0) 1
   DM 314 (43.1) 1.95 1.66-2.30
CKD stage
   G1 12 (3.4) 1
   G2 48 (11.5) 4.10 2.17-7.74
   G3a 66 (18.4) 7.46 4.00-13.89
   G3b 149 (32.4) 14.04 7.72-25.51
   G4 275 (59.5) 41.19 22.85-74.27
   G5 112 (84.8) 145.24 79.12-266.64
Multivariable analysis by Cox proportional hazards model.
CI, confidence interval; CKD, chronic kidney disease; DM, diabetes mellitus; G, 
grade.
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PWV was also shown to be a risk factor for renal outcome. 
High baPWV, if accompanied by a high heart-to-femoral 
PWV (hfPWV), was shown to be associated with rapid 
eGFR decline, suggesting that central and peripheral 
PWVs may simultaneously affect rapid eGFR decline [42].
Dietary protein restriction may be beneficial to CKD 
patients by delaying CKD progression. However, it may 
be harmful to patients at risk of PEW. Therefore, dietary 
protein restriction may be a double-edged sword for CKD 
patients. The KNOW-CKD analyzed associations between 
dietary protein intake (DPI) assessed by 24-hour urine 
nitrogen excretion [43], PEW, and renal outcome. Low 
DPI was found to be associated with PEW, which may 
attenuate the potential benefits of a low-protein diet on 
CKD progression. Therefore, caution about the risk of 
PEW particularly needs to be expressed to patients [44].
To date, several biochemical markers shown to be in-
dependently associated with CKD progression by the 
KNOW-CKD study are hyperuricemia [45], low urine 
osmolality [46], low urine chloride [47], and low urine 
potassium [48] levels.
CV outcome and death in KNOW-CKD
As mentioned above, among 2,238 subjects, there were 
107 deaths and 165 fatal or non-fatal CV events as of 
March 31, 2019. Compared with the incidences of renal 
end-points, the incidences of CV outcomes and death 
were relatively low, as shown in Table 3. Observational 
studies from Western CKD populations reported that 
patients with CKD have a higher risk of death than risk of 
progression to ESRD [49]. However, in our Korean CKD 
population, incidences of any CV event (16.2 per 1,000 
patient-years) or all-cause death (10.1 per 1,000 patient-
years) were much lower than those of ESRD, which were 
57 per 1,000 patient-years. This is similar to the report 
from Japanese CKD subjects [50] and was also shown in 
a recent international collaborative study comparing the 
outcomes of various CKD cohorts [51]. Investigation on 
the risk factors of adverse CV outcome or death will be 
conducted when a significant number of end-points is 



























































Figure 2. Adjusted Kaplan-Meier curve 
for cumulative renal events according 
to metabolic subtypes [40], reproduced 















Measured 24-hour urinary sodium excretion (mEq/day)
Figure 3. Association of measured 24-hour urinary sodium ex-
cretion with hazard ratio of chronic kidney disease progression 
in fully-adjusted model [41]. Note the relatively linear relationship 
between measured 24-hour urinary sodium excretion and risk of 
composite renal outcomes at the reference of urinary sodium excre-
tion ≥ 120 mEq/day.
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Biomarker discovery in CKD
Biomarkers are molecules that are objectively mea-
sured and evaluated as an indicator of normal biological 
process, pathologic process, or pharmacologic response. 
Recent advances in molecular biology, functional ge-
nomics, and proteomics have elucidated many candidate 
biomarkers in acute kidney injury and CKD, such as 
neutrophil gelatinase-associated lipocalin, kidney injury 
molecule-1, and liver-type fatty acid-binding protein. 
The KNOW-CKD has found several biomarker candidate 
molecules that can predict major adverse outcomes of 
CKD. Candidate biomarkers of CKD outcomes are cys-
tatin C [21], albuminuria [52], adiponectin [53-58], FGF23 
[31,59], high density lipoprotein cholesterol [60], tropo-
nin T [61] (Fig. 4), hepcidin [26,30], Klotho [28,62], OPG 
[63], and various urinary markers [46,47,64-66]. The main 
results of the biomarker studies are described in Table 5 
[28,53-66].
International collaborations for CKD study
The incidence, prevalence, and clinical outcomes of 
CKD/ESRD vary depending on country and ethnicity 
[67,68]. The KNOW-CKD has been actively participat-
ing in the International Network of CKD Cohort Studies 
(iNET-CKD) [69] in pursuit of the factors explaining such 
differences through inter-ethnic and international com-
parison and meta-analysis.
In one recent meta-analysis [70], the iNET-CKD report-
ed crude prevalence of uncontrolled BP among 17 cohort 
studies, including 34,602 individuals with eGFR < 60 
mL/min/1.73 m2 and treated hypertension adjusted for 
potential confounders. Crude prevalence of BP ≥ 140/90 
mmHg ranged from 28% to 61%. Adjusted prevalence 
ratios indicated poorer hypertension control in cohorts 
from European countries, India, and Uruguay, and better 
control in North America and high-income Asian coun-
tries including Korea and Japan. Particularly, the KNOW-
CKD exhibited the lowest prevalence of uncontrolled 
hypertension (27.3%) among the 17 participating CKD 
cohorts.
Another international meta-analysis study compared 
the longitudinal outcomes of CKD across eight iNET-CKD 
cohorts [51]. The risks of CKD progression, ESRD, death, 
and CVD vary across countries even after adjusting for 
age, sex, comorbidities, and baseline laboratory results. 
The KNOW-CKD cohort population, as compared to the 
other seven cohorts in Europe, Japan, North America, 
and South America, exhibited relatively lower incidence 
of all-cause mortality, while exhibiting higher incidences 
of CKD progression and ESRD, after adjustment (Fig. 5).
Taken together, the findings from the two international 
comparison studies above warrant a search for the spe-
cific genetic, socio-economic, and cultural factors in the 
Korean CKD population that explain this difference.
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Figure 4. The association between high-sensitivity troponin T (hs-TnT) and longitudinal echocardiographic changes [61]. (A) Left 
ventricular hypertrophy: adjusted to age, sex, mean arterial pressure, diabetes mellitus (DM), hypertension (HTN), coronary artery disease, 
chronic kidney disease (CKD) stage, body mass index (BMI), high density lipoprotein cholesterol (HDL-C), triglyceride (TG), hemoglobin. (B) 
Diastolic dysfunction: adjusted to age, sex, DM, HTN, CKD stage, BMI, HDL-C, TG, C-reactive protein, smoking history. 
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KNOW-CKD Phase II
The KNOW-CKD has recently launched Phase II enroll-
ment for 2019 through 2021 (Table 6). The aims of the 
KNOW-CKD Phase II study are as follows: 1) to enlarge 
the total pool of CKD patients in the cohort, particularly 
those with eGFR < 60 mL/min/1.73 m2 and high risks of 
renal progression 2) to focus more on DN and HTN, and 
3) to emphasize the health habits of the CKD patients by 
obtaining more information on dietary patterns, nutri-
tional status, and cognitive functions. It is expected that 
the KNOW-CKD Phase II will not only reinforce the sta-
tistical power of the KNOW-CKD Phase I but also provide 
robust scientific evidence on the significance of health 
habits and dietary modification on the CKD outcomes.
Summary and conclusion
As the nation’s largest CKD cohort, the KNOW-CKD 
has relentlessly pursued answers to the basic questions 
on clinical courses and elucidation of the risk factors 
for adverse outcomes from the Korean CKD population. 
Particularly, among various aspects of CKD, greater em-
phases were placed upon socio-economics, nutrition and 
Table 5. Summary of biomarker discovery studies in KNOW-CKD
Time frame Biomarker Outcome Remarks
C Adiponectin MS Hypoadiponectinemia is independently associated with the metabolic syndrome in CKD [53].
C Adiponectin PEW High serum adiponectin is independently associated with PEW. Among PEW indicators, 
serum adiponectin is closely associated with urine creatinine excretion as an indirect 
measure of muscle mass [54].
C Adiponectin Albuminuria and 
renal function
Serum adiponectin is higher in patients with increasing albuminuria, and these levels are 
associated with albuminuria, renal insufficiency and lipid profiles [55].
C Adiponectin hfPWV The independent and significant correlation of serum adiponectin concentration with 
hfPWV in CKD implicates adiponectin in CKD-associated aortic stiffness [56].
C, L Adiponectin Anemia A high serum adiponectin level is independently associated with a low hemoglobin level 
and predicts the development of anemia in patients with CKD [57].
L Adiponectin Renal event Serum adiponectin may be a biomarker of renal dysfunction rather than a true risk factor 
in CKD progression [58].
C FGF23 CAC High serum FGF23 was associated with CAC in CKD patients with high adiponectin, but not 
in those with low adiponectin [59].
L HDL cholesterol Renal event A U-shaped association was observed between serum HDL-C levels and adverse renal 
outcomes [60].
C, L hs-TnT LV structure and 
function, new LVH
hs-TnT is strongly associated with alterations of LV structure and diastolic dysfunction for 
both eGFR strata. Baseline hs-TnT levels are predictive of new LVH on follow-up [61].
C Klotho LV mass index Serum Klotho is an independent biomarker of left ventricular mass index [28].
C Klotho MS MS is prevalent in CKD. Serum Klotho is inversely associated with the presence of MS in 
patients with CKD [62].
C OPG baPWV Non-traditional, kidney-related cardiovascular risk factors in addition to traditional 
cardiovascular risk factors are related to serum level of OPG in CKD. Serum OPG level is 
significantly related to baPWV [63].
C Urine creatinine 
excretion
PWV 24-hour urine creatinine is a marker of muscle mass. Low creatinine excretion is 
associated with high PWV, suggesting a relationship between decreased muscle mass 
and arterial stiffness [64].
L Urine Na/K ratio Renal event The Na/K ratio in urine is an index of dietary sodium and potassium intake. The higher Na/
K ratio in 24-hour urine collection is associated with higher rate of CKD progression [65].
C, L Urine AGT Urinary K excretion, 
renal event
High urinary AGT level is associated with increased urinary K excretion and renal outcome 
in patients with PKD [66].
AGT, angiotensinogen; baPWV, brachial-to-ankle pulse wave velocity; C, cross-sectional; CAC, coronary artery calcification; CKD, chronic kidney disease; FGF23, 
fibroblast growth factor 23; HDL-C, high density lipoprotein cholesterol; hfPWV, heart-to-femoral pulse wave velocity; hs-TnT, high sensitivity troponin T; KNOW-
CKD, KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease; L, longitudinal; LV, left ventricle; LVH, left ventricular hypertrophy; MS, metabolic 
syndrome; OPG, osteoprotegerin; PEW, protein-energy wasting; PKD, polycystic kidney disease.
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QOL, health habits, CKD progression, CV comorbidity 
and outcome, anemia, mineral bone disease, biomarker 
discovery, and international and inter-ethnic compari-
son. By following the subjects for more than 10 years, the 
KNOW-CKD will eventually offer a prediction model for 
the long-term consequences of CKD such as the occur-
rences of ESRD, CVD, and death, thereby enabling the 
identification and treatment of the at-risk population that 
requires extra medical attention.
The KNOW-CKD Investigator Group
Patient Recruitment. Seoul National University Hos-
pital, Curie Ahn, MD, Kook-Hwan Oh, MD (PI), Hajeong 
Lee, MD, Seung Seok Han, MD, Hyunjin Ryu, MD, Eun-
jeong Kang, MD, Minjung Kang, MD, Youngok Ko, RN, 
Jeongok So, RN, and Aram Lee, RN. Seoul National Uni-
versity Bundang Hospital, Dong Wan Chae, MD (SubPI), 
Yong Jin Yi MD, Hyun Jin Cho, RN and Jung Eun Oh RN. 
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10 9030 50 70
Incidence rates of CKD progression
(events/1,000 person-years)
Cochran's Q: 243.07 Df (6) < 0.001p
I (95% CI): 97.5% (96.4 98.3%)
2
A
B Incidences of eGFR halving or ESRD
Incidences of all cause death
Figure 5. Adjusted incidence rates of all-cause death (A) and composite of estimated glomerular filtration rate (eGFR) halving or 
end-stage renal disease (ESRD) (B) across the International Network of Chronic Kidney Disease studies (iNET-CKD) [51], repro-
duced with permission. Adjusted incidence rates were estimated through direct standardization using the total population from all study 
groups as the standard. Adjustments included age, sex, and eGFR at baseline. Individuals included were 18 years and older and had an 
eGFR assessment at baseline between 15 and 60 mL/min per 1.73 m2. Cochran’s Q and I2 statistics were estimated to assess heterogene-
ity in incidence rates across iNET-CKD studies. 
AUS, Australia; CI, confidence interval; CAN, Canada; CAN-PREDDICT, Canadian Study of Prediction of Death, Dialysis and Interim Cardiovas-
cular Events; CKD-JAC, Chronic Kidney Disease Japan Cohort; CKD-QLD, Chronic Kidney Disease in Queensland; CRIC, Chronic Renal Insuffi-
ciency Study; GBR, Great Britain; JPN, Japan; KNOW-CKD, KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease; KOR, 
Republic of Korea; NRHP, National Renal Healthcare Program; RIISC, Renal Impairment in Secondary Care; URY, Uruguay; USA, United States 
of America.
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Table 6. Basic design and enrollment in Phase I and II of the 
KNOW-CKD study
Characteristics Phase I Phase II
Timing of enrollment (year) 2011-2016 2019-2021
Number of participating 
centers
9 13
Number enrolled 2,238 1,500a
Age (yr) 20-75 45-79





CKD, chronic kidney disease; eGFR, estimated glomerular filtration; KNOW-CKD, 
KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease.
aPlanned.
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